Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 4/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.35 |
| ▸ | BCAT2 | O15382 | 4/20 | 0.35 |
| ▸ | BCAT1 | P54687 | 4/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20267715 | 0.81 | L3MBTL1 (0.41) | CDK4CCND1HCAR1 | |
| SCHEMBL30537048 | 0.81 | L3MBTL1 (0.41) | CDK4CCND1HCAR1 | |
| SCHEMBL6506928 | 0.80 | TRPV4 (0.36) | KDM4EARBCAT2BCAT1PGR | |
| SCHEMBL2526431 | 0.79 | CDK4 (0.38) | CDK4CCND1KDM4EHCAR1 | |
| SCHEMBL9139297 | 0.77 | BCAT2 (0.40) | GRIN1GRIN2BKDM4EBCAT2BCAT1 | |
| SCHEMBL2530113 | 0.76 | L3MBTL1 (0.41) | FFAR4KDM4EARSCN9A | |
| SCHEMBL14535281 | 0.76 | CDK4 (0.36) | CDK4CCND1GRIN1GRIN2BHCAR1 | |
| SCHEMBL4038241 | 0.73 | KDM4E (0.39) | KDM4EARSCN9A | |
| SCHEMBL2076032 | 0.71 | EGLN2 (0.40) | KDM4EARSCN9A | |
| SCHEMBL23565228 | 0.71 | ABHD16A (0.44) | HCAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101360752-B | Hiv integrase inhibitors | BRISTOL MYERS SQUIBB CO | 2012-09-05 | — | — | CN | disclosed |
| US-8039458-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039458-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039458-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| EP-1948666-B1 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-17 | — | — | EP | disclosed |
| EP-1948666-B1 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-17 | — | — | EP | disclosed |
| CN-101360752-A | HIV integrase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-02-04 | — | — | CN | disclosed |
| WO-2007061714-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070111984-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-17 | — | — | US | disclosed |
| US-20070111984-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-17 | — | — | US | disclosed |
| US-20070111984-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111984-A1 | HIV integrase inhibitors | TYMP, POLN, IMPDH1 | CDK4 150/4885CCND1 595/4885FFAR4 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.